Efficacy Study in Lumbosacral Radiculopathy

NCT01110057 | Completed Phase 2

• 1 other identifier: 113049
• Study Type: interventional
• Target: 142
• Locations: 5 countries
• Sites: 17

Brief Summary

This study will be a double-blind, placebo-controlled, parallel group study. After enrolment and initial assessments, subjects will receive 35 days of study medication. During this treatment period, they will be randomised to either oral GW856553 7.5mg BID or matching placebo in a 1:1 ratio. Sufficient numbers of subjects will be recruited to obtain 128 evaluable subjects.

Conditions

Pain, Neuropathic

Keywords

p38 kinase inhibitor; male and female; patients

Outcome Measures

Primary Outcomes (1)

• Change in average daily neuropathic pain score from Baseline up to Week 5 (Week 4 of double blind treatment) of treatment

  The scores were analyzed based on the 11 point Pain Intensity Numerical Rating Scale (PI-NRS) with 0 score indicating no pain and score of 10 indicating maximum pain. The adjusted mean values are represented as least square mean (LS mean) values.

  Baseline (Day -7 to Day -1) and up to 5 weeks

Secondary Outcomes (17)

• Change in average daily pain intensity rating score (PI-NRS) from Baseline (Day -7 to Day -1) to 5 Weeks

  Baseline (Day -7 to Day -1) and up to 5 weeks

• Change in pain quality on the Short-Form McGill Pain Questionnaire (SF-MPQ) from Baseline up to 5 weeks.

  Baseline (Day -7 to Day -1) and up to 5 weeks

• Number of participants with intensities of pain by SF-MPQ method over 5 weeks

  From Baseline (Day -7 to Day -1) up to 5 weeks

• Change in Galer Neuropathic Pain Scale score from Baseline up to Week 5

  Baseline (Day -7 to Day -1) and up to 5 weeks

• Percentage of participants with more than or equal to (>=) 30% and >=50% reduction in average daily pain score relative to baseline up to 5 weeks

  Baseline (Day -7 to Day -1) and up to 5 weeks

Study Arms (2)

Active

EXPERIMENTAL

GW856553

Drug: GS856553

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

Placebo DRUG

Placebo to match GW856553

Placebo

GS856553 DRUG

GW586553 7.5mg bid

Active

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects aged 18 - 80 years inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of:
• Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 14 days after the last dose of study medication. Male subjects must agree to use the contraception methods listed in the protocol
• A diagnosis of neuropathic pain due to lumbosacral radiculopathy with the following characteristics:
• Pain perceived in one or both lower limbs at sites consistent with the area innervated by the L4, L5 or S1 nerve roots, with or without other sensory symptoms in the affected areas; (typically, the pain may be perceived in the buttock, thigh, calf, leg, foot or toes).
• History of the pain suggestive that the cause of lumbosacral radiculopathy is due to injury of the lumbosacral nerve root(s) by degenerative disease of the vertebrae in the lumbosacral spine or associated soft tissues including the intervertebral discs, or secondary to spinal injury and not due to infection/abscess, haematoma or malignancy.
• Duration of pain should be at least 12 weeks since onset.
• Intensity of pain should be stable for the 2 weeks prior to Screening, based on clinical history.
• As part of the neurological examination, the investigator must also conduct the procedures specified in the Standardised Evaluation of Pain \[Neuropathic Pain\] (StEP) instrument \[Scholz, 2009\]2, and to calculate the total score. In the clinical opinion of the investigator, the diagnosis of lumbosacral radiculopathy should be supported by at least one of the following features at Screening or documented in the medical notes in relation to the current symptoms:
• Pain/sensory disturbance in dermatomal/myotomal distribution precipitated or exacerbated by straight leg raising (the straight leg raising test should be performed as specified in StEP; Neurological examination of lower limbs shows impaired muscle power, sensory function or deep tendon reflexes in the territory of the affected nerve roots; The total StEP score is greater than 4 (indicative of lumbosacral radiculopathy as the cause of the pain); Electromyographic (EMG) evidence of denervation in muscles innervated by the affected nerve roots; Quantitative sensory tests (QST) showing evidence of altered sensory thresholds in dermatomes innerved by the affected nerve roots;
• At Screening, if the investigator is satisfied with the diagnosis based on clinical review, or if results from such investigations related to the current symptoms are already documented in the medical notes, then it is not essential for the investigator to conduct computerised tomography (CT)/magnetic resonance imaging (MRI), EMG or QST.

You may not qualify if:

• Subjects on medications for neuropathic pain (may only be included in the study if they have been on stable doses of such medications for at least 4 weeks prior to baseline period (Day -7) and continue with such stable doses during the study.
• Subjects' baseline average daily pain score for neuropathic pain due to LSR on the PI-NRS, calculated as the average of their daily PI-NRS scores over the baseline period (Day -7 to Day -1), is greater than or equal to 4 on the PI-NRS, after wash-out of prohibited medications. Male subjects must agree to use the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 14 days after the last dose of study medication.
• Subject has provided full written informed consent prior to the performance of any protocol-specified procedure, which includes compliance with the requirements and restrictions listed in the consent form.
• Subjects who, in the opinion of the Investigator, are unable to reliably delineate or assess their own pain by anatomical location/distribution (e.g. can the subject reliably tell the difference between their back pain and their lower limb pain and rate their intensity separately ?).
• Subjects with lumbar canal stenosis in which the pain in the lower limbs occur solely on walking and not at rest.
• A positive pre-study drug/alcohol screen.
• A positive test for HIV antibody or positive history of HIV.
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• History of any liver disease within the last 6 months \[with the exception of known Gilbert's disease\].
• History of excessive regular alcohol consumption within 6 months of the study.
• History or presence of significant cardiovascular, gastro-intestinal, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs which, in the opinion of the Investigator may interfere with the study procedures or compromise subject safety.
• History or presence of any clinically significant abnormality in vital signs / ECG / laboratory tests, or have any medical or psychiatric condition, which, in the opinion of the Investigator, may interfere with the study procedures or compromise subject safety.
• Subject has clinical evidence of recent major depression (by medical history) except those subjects already controlled by anti-depressants at screening.
• Subjects who, in the clinical judgement of the investigator, may be malingering or be motivated by secondary gain from participation in the study, will be excluded.
• Unable to stop and remain abstained from non-pharmacological treatments for their neuropathic pain during the study

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (17)

GSK Investigational Site

Hoersholm, 2970, Denmark

Location

GSK Investigational Site

Odense C, 5000, Denmark

Location

GSK Investigational Site

Bois-Guillaume, 76230, France

Location

GSK Investigational Site

Boulogne-Billancourt, 92100, France

Location

GSK Investigational Site

Lyon, 69394, France

Location

GSK Investigational Site

Nice, 06002, France

Location

GSK Investigational Site

Paris, 75181, France

Location

GSK Investigational Site

Schönau, Baden-Wurttemberg, 69250, Germany

Location

GSK Investigational Site

Munich, Bavaria, 80333, Germany

Location

GSK Investigational Site

Leipzg, Saxony, 04109, Germany

Location

GSK Investigational Site

Hamburg, 20255, Germany

Location

GSK Investigational Site

Hamburg, 22767, Germany

Location

GSK Investigational Site

Hamar, 2317, Norway

Location

GSK Investigational Site

Oslo, 0027, Norway

Location

GSK Investigational Site

Trondheim, 7030, Norway

Location

GSK Investigational Site

Örebro, SE-703 62, Sweden

Location

GSK Investigational Site

Stockholm, SE-115 22, Sweden

Location

Related Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

MeSH Terms

Conditions

Neuralgia

Condition Hierarchy (Ancestors)

Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2010
• First Posted: April 23, 2010
• Study Start: January 7, 2010
• Primary Completion: August 23, 2010
• Study Completion: August 23, 2010
• Last Updated: June 8, 2017

Record last verified: 2017-06

Data Sharing

• IPD Sharing: Will share

Locations

FR (5); SE (2); DE (5); DK (2); NO (3)